Date: 2014-01-06
Type of information: Licensing agreement
Compound: cell therapy program for cardiovascular applications, including CAP-1002
Company: Janssen Biotech, a J&J company (USA - NJ) - Capricor Therapeutics (USA - CA)
Therapeutic area: Cardiovascular diseases
Type agreement: licensing collaboration
Action mechanism: cell therapy. CAP-1002, Capricor\'s lead product candidate, is a proprietary allogeneic adult stem cell therapy for the treatment of heart disease. The product is derived from donor heart tissue. The cells are expanded in the laboratory using a specialized process and then introduced directly into a patient\'s heart via infusion into a coronary artery using standard cardiac catheterization techniques.
Disease:
Details: * On January 6, 2014, Capricor Therapeutics announced that it has executed a collaboration agreement and exclusive license option with Janssen Biotech. Under the terms of the agreement, Capricor and Janssen agreed to collaborate on the development of Capricor\'s cell therapy program for cardiovascular applications, including its lead product, CAP-1002. CAP-1002 is an allogeneic cardiosphere-derived cell (CDC) therapeutic under evaluation in patients who have suffered a large myocardial infarction. Pursuant to the agreement, Capricor and Janssen will collaborate on elements of cell manufacturing development. Capricor will contribute to the costs of the manufacturing collaboration, and will receive an upfront payment of $12.5 million from Janssen.
Financial terms: Under the terms of the agreement, Janssen has the right to enter into an exclusive license agreement for CAP-1002 at any time until sixty days following delivery by Capricor of the six-month follow-up results from Phase II of Capricor\'s ALLSTAR clinical trial for CAP-1002. If Janssen exercises its option rights, Capricor will be eligible to receive up to $325 million in additional payments. In addition, a royalty would be paid on commercial sales of CAP-1002.
Latest news:
